Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878814 | 1.00 | LMNA (1.00) | LMNACYP3A4MAPTMEN1NR1I2 | |
| Exalamide SCHEMBL27702423 | 1.00 | LMNA (1.00) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL29603307 | 1.00 | LMNA (1.00) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL874312 | 1.00 | LMNA (1.00) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL5147507 | 1.00 | LMNA (1.00) | LMNACYP3A4MAPTMEN1NR1I2 | |
| Exalamide SCHEMBL151112 | 1.00 | LMNA (1.00) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL9417650 | 1.00 | LMNA (1.00) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL29627441 | 1.00 | LMNA (1.00) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL4656110 | 1.00 | LMNA (1.00) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL7649315 | 1.00 | LMNA (1.00) | LMNACYP3A4MAPTMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4110277-B1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-4110276-B1 | COMPOSITIONS COMPRISING ALKANEDIOLS | SYMRISE AG (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-4477264-A2 | COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ACTIVE INGREDIENTS | Symrise AG (DE) | 2024-12-18 | — | — | EP | claimed |
| US-20230293404-A1 | Compositions Comprising Natural Polymers and One or More (Bio)-Alkanediols | SYMRISE AG (DE) | 2023-09-21 | — | — | US | claimed |
| EP-4103143-A1 | COMPOSITIONS COMPRISING NATURAL POLYMERS AND ONE OR MORE (BIO)-ALKANEDIOLS | Symrise AG (DE) | 2022-12-21 | — | — | EP | claimed |
| WO-2022122132-A1 | COMPOSITIONS COMPRISING NATURAL POLYMERS AND ONE OR MORE (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | claimed |
| WO-2022122890-A1 | COMPOSITIONS COMPRISING NATURAL POLYMERS AND ONE OR MORE (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | claimed |
| EP-4103144-B1 | COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4110277-B1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | SYMRISE AG (DE) | 2026-04-09 | — | — | US | disclosed |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2026-02-19 | — | — | US | disclosed |
| EP-4110276-B1 | COMPOSITIONS COMPRISING ALKANEDIOLS | SYMRISE AG (DE) | 2026-01-28 | — | — | EP | disclosed |
| EP-4340807-B1 | HAIR COLOR COMPOSITIONS FOR MITIGATING COLOR LOSS | LUBRIZOL ADVANCED MAT INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20030175366-A1 | Plant Extracts and Methods of Treating Skin Therewith | COGNIS FRANCE, S.A. (FR) | 2003-09-18 | — | — | US | disclosed |
| US-20030170298-A1 | Proliposomal encapsulated preparations | COGNIS IBERIA S.L. (ES) | 2003-09-11 | — | — | US | disclosed |
| US-20030161847-A1 | Use of hydroxyethers in cosmetic and pharmaceutical preparations | COGNIS IP MANAGEMENT GMBH (DE) | 2003-08-28 | — | — | US | disclosed |
| US-20030138394-A1 | Cosmetic and/or pharmaceutical preparations that contain an extract of the plant argania spinosa | COGNIS FRANCE S.A. (FR) | 2003-07-24 | — | — | US | disclosed |
| US-20030113354-A1 | Granular solid with monodisperse particle size distribution | COGNIS IP MANAGEMENT GMBH (DE) | 2003-06-19 | — | — | US | disclosed |
| US-20030068364-A1 | Pro-liposomal encapsulated preparations (iv) | COGNIS IBERIA S.L (ES) | 2003-04-10 | — | — | US | disclosed |
| US-20030064106-A1 | Microcapsules-vi | COGNIS IBERIA, S.L. (ES) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030113354-A1 | Granular solid with monodisperse particle size distribution | U2AF2, SDHA, SDHB | LMNA 3160/4885CYP3A4 2354/4885MAPT 1079/4885 |
| US-20030138394-A1 | Cosmetic and/or pharmaceutical preparations that contain an extract of the plant argania spinosa | ARG1, ARG2, CUTA | LMNA 1498/4885CYP3A4 611/4885MAPT 1603/4885 |
| US-20030064106-A1 | Microcapsules-vi | CHMP4B, LIPA, PHOSPHO1 | LMNA 909/4885CYP3A4 3932/4885MAPT 2223/4885 |
| US-20030161847-A1 | Use of hydroxyethers in cosmetic and pharmaceutical preparations | CYP8B1, SQLE, HSD17B7 | LMNA 3554/4885CYP3A4 153/4885MAPT 2209/4885 |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | RBP4, LRAT, RARB | LMNA 2563/4885CYP3A4 2860/4885MAPT 781/4885 |
| US-20030068364-A1 | Pro-liposomal encapsulated preparations (iv) | PHOSPHO1, LIPA, PLIN5 | LMNA 125/4885CYP3A4 2170/4885MAPT 1456/4885 |
| US-20230293404-A1 | Compositions Comprising Natural Polymers and One or More (Bio)-Alkanediols | ACMSD, CUTA, DDC | LMNA 3696/4885CYP3A4 3177/4885MAPT 662/4885 |
| US-20030170298-A1 | Proliposomal encapsulated preparations | LIPA, PLIN5, PNLIP | LMNA 1888/4885CYP3A4 4432/4885MAPT 938/4885 |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | PTGS2, PTGES2, PTGS1 | LMNA 2747/4885CYP3A4 2277/4885MAPT 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.